Aurigene Discovery Technologies Limited
Clinical trials sponsored by Aurigene Discovery Technologies Limited, explained in plain language.
Biotechnology company focused on drug discovery and development.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill AUR107 enters first human tests for tough cancers Results expected Jan 2027 (estimated)
- New pill aims to fight advanced lymphoma when other treatments fail Results expected Jan 2027 (estimated)
- New pill aims to tame advanced lymphomas in early trial Results expected Aug 2027 (estimated)
-
New pill aims to tame advanced lymphomas in early trial
Disease control Recruiting nowThis early-phase study tests an experimental oral drug called AUR108 in adults with relapsed advanced lymphomas. The main goals are to check the drug's safety, find the right dose, and see how the body processes it. About 40 participants will take the pill, and researchers will m…
Phase 1 • Sponsor: Aurigene Discovery Technologies Limited • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New pill AUR107 enters first human tests for tough cancers
Disease control Recruiting nowThis Phase 1 trial is testing an oral drug called AUR107 in 50 adults with advanced solid tumors that have come back after prior treatment. The study aims to find a safe dose and understand how the drug moves through the body. It is the first time AUR107 is being tested in humans…
Phase 1 • Sponsor: Aurigene Discovery Technologies Limited • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New pill aims to fight advanced lymphoma when other treatments fail
Disease control Recruiting nowThis early-stage trial tests an oral drug called AUR112 in 40 adults with relapsed advanced lymphoma. The main goals are to check safety, find the right dose, and see how the drug moves through the body. It is the first time this drug is being tested in humans.
Phase 1 • Sponsor: Aurigene Discovery Technologies Limited • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC